Evidence map›Paper›PMID 37775081›Full record

ArticlePreventive medicine2023

Association between maternal prenatal cannabis use and missed child preventive care visits in an integrated health care delivery system in Northern California.

Lyndsay A Avalos, Nina Oberman, Stacey E Alexeeff, Lisa A Croen, Sara R Adams, Meghan Davignon, Kelly C Young-Wolff

Abstract read
In one paragraph

Article in Preventive medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lyndsay A AvalosDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America. Electronic address: Lyndsay.A.Avalos@kp.org.
Nina ObermanDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America.
Stacey E AlexeeffDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America.
Lisa A CroenDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America.
Sara R AdamsDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America.
Meghan DavignonThe Permanente Medical Group, Oakland, CA, United States of America.
Kelly C Young-WolffDivision of Research, Kaiser Permanente Northern California, Oakland, CA, United States of America; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, United States of America.

Funding

Maternal Marijuana Use During Pregnancy, Marijuana Legalization, and Adverse Obstetrical and Neonatal Outcomes: A 12-year Cohort StudyR01DA047405 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI AVALOS, LYNDSAY AMMON, YOUNG-WOLFF, KELLY CORINNE · 2019 to 2023
$3.5M
Impact of in utero Marijuana Exposure on Neurodevelopment, Behavior and Mental Health: A Longitudinal Birth Cohort StudyR01DA048033 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI AVALOS, LYNDSAY AMMON, YOUNG-WOLFF, KELLY CORINNE · 2020 to 2025
$3.1M
Identifying Risk Factors for Prenatal Substance and Polysubstance UseK01DA043604 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI YOUNG-WOLFF, KELLY CORINNE · 2017 to 2021
$907k
NIDA NIH HHS K01 DA043604NIDA NIH HHS R01 DA047405NIDA NIH HHS R01 DA048033
6 · The paper itself

Abstract

The periodicity of well-child visits recommended by the American Academy of Pediatrics emphasizes the importance of continuity of care in health management. Exposure to cannabis in utero has been associated with adverse development, and adherence to well-child visits is critical for earlier detection and intervention. To assess whether maternal prenatal cannabis use was associated with missed well-child visits in the first three years after birth we conducted a longitudinal cohort study in Kaiser Permanente Northern California of pregnant individuals and their children born between January 1, 2011 and December 31, 2018. Maternal prenatal cannabis use was defined as any self-reported cannabis use since becoming pregnant and/or a positive urine toxicology test for cannabis during pregnancy. Well-child visits were defined as an encounter for a well-child visit or physical exam and categorized into seven time periods from birth to 36 months. Modified Poisson regression models were conducted. Of the 168,589 eligible pregnancies, 3.4% screened positive for maternal prenatal cannabis use. Compared to no use, maternal prenatal cannabis use was associated with more missed well-child visits at every time period; (missed 12-month visit: adjusted relative risk (aRR): 1.43, 95%CI: 1.32-1.54; missed 3-year visit: aRR: 1.15, 95%CI: 1.11-1.20). Maternal prenatal cannabis use was also associated with missing two or more well-child visits through 36 months of age (35.8% among cannabis users vs. 23.0% among non-users, Χ

Indexed as

CannabisCaliforniaChildChild HealthDelivery of Health CareFemaleHumansLongitudinal StudiesPregnancyPrenatal CarecannabisChild developmentPregnancyPrenatal substance usePreventive careWell-child visits

Identifiers

PMID37775081
PMCPMC10849893

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.